Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azepane SCHEMBL27704297 | 1.00 | TACR1 (0.40) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Piperidine SCHEMBL27922706 | 0.98 | TSHR (0.40) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Pyrrolidine SCHEMBL27776262 | 0.98 | TACR1 (0.41) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Azetidine SCHEMBL27976635 | 0.95 | TSHR (0.41) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Piperazine SCHEMBL28083640 | 0.91 | TACR1 (0.42) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Piperazine SCHEMBL27484195 | 0.91 | TACR1 (0.42) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Pyrrolidine SCHEMBL28317443 | 0.91 | KMT2A (0.38) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| Piperazine SCHEMBL28258210 | 0.89 | TACR1 (0.41) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27873296 | 0.89 | TSHR (0.46) | SLC6A2SLC6A3TSHRALDH1A1MAPK1 | |
| SCHEMBL17956886 | 0.83 | HTR2C (0.40) | TACR1HTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103140484-B | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH | 2015-04-22 | — | — | CN | claimed |
| CN-103140484-A | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH | 2013-06-05 | — | — | CN | claimed |
| CN-101679432-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2010-03-24 | — | — | CN | claimed |
| CN-101541751-A | Quinoline compounds | WYETH CORP (US) | 2009-09-23 | — | — | CN | claimed |
| US-6677483-B2 | DISSOLVING DIETHYLENETRIAMINEPENTAACETIC- BISANHYDRIDE OF FORMULA IN DIMETHYL SULFOXIDE OR IN DIMETHYLFORMAMIDE OR IN A MIXTURE; ADDING SOLUBILIZER, AN AUXILIARY BASE AND A MONOAMINE OR DIAMINE, HEATING | SCHERING AG (DE) | 2004-01-13 | — | — | US | claimed |
| US-20020155065-A1 | Process for the production of monoamides of DTPA | SCHERING AG (DE) | 2002-10-24 | — | — | US | claimed |
| CN-110526929-A | Heteroaromatic compounds, its pharmaceutical composition and its application | GUANGZHOU HENOVCOM BIOSCIENCE CO LTD | 2019-12-03 | — | — | CN | disclosed |
| CN-105960404-B | The inhibitor of bruton's tyrosine kinase | 药品循环有限责任公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-107001271-B | Hydroxyamidine derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2019-05-10 | — | — | CN | disclosed |
| CN-109689611-A | METHOD FOR PRODUCING ORGANIC COMPOUND | 株式会社钟化 | 2019-04-26 | — | — | CN | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109311880-A | For treating and preventing hepatitis b virus infected new tetrahydropyridine miazines compound | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109232540-A | A kind of substituted benzimidazole derivative and application | 深圳市坤健创新药物研究院 | 2019-01-18 | — | — | CN | disclosed |
| CN-101242834-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-101171230-A | Heterocyclic-substituted alkanamides useful as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| CN-101163697-A | Pyrrole derivatives as inhibitors of DNA gyrase and topoisomerase | ASTRAZENECA AB (SE) | 2008-04-16 | — | — | CN | disclosed |
| CN-101103020-A | CGRP receptor antagonists | MERCK & CO INC (US) | 2008-01-09 | — | — | CN | disclosed |
| CN-1845908-A | 5-substituted quinazolinone derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-11 | — | — | CN | disclosed |
| CN-1780840-A | Pyrazolo [1, 5-a ] pyrimidine derivatives | TEIJIN PHARMA LTD (JP) | 2006-05-31 | — | — | CN | disclosed |
| CN-1735441-A | Combination for treating attention deficit hyperactivity disorder | PHARMACIA & UPJOHN CO LLC (US) | 2006-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155065-A1 | Process for the production of monoamides of DTPA | NAAA, PAM, DNPEP | TACR1 2218/4885HTR1A 1204/4885SLC6A2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.